FIGO stage IV gestational choriocarcinoma misdiagnosed as pulmonary tuberculosis: A case report

LINGYUN YANG, PANG XU, MINGRONG XI and HONGJING WANG

Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China

Received September 15, 2014; Accepted June 5, 2015

DOI: 10.3892/ol.2015.3443

Abstract. Choriocarcinoma is a rare, highly malignant neoplasm, which may occur during or following any type of pregnancy. This tumor often demonstrates rapid hematogenous spread to multiple organs, and is associated with high human chorionic gonadotropin (HCG) levels and a good response to chemotherapy. In the present study, the case of a 29-year-old female with distant metastatic choriocarcinoma [International Federation of Gynecology and Obstetrics (FIGO) stage IV; World Health Organization score, 15], who was misdiagnosed with pulmonary tuberculosis at a local hospital is presented. The major failure in the diagnosis of this case was that the patient's serum β-HCG levels were ignored initially. However, the patient received combined treatment with systematic multi-agent chemotherapy, whole-brain radiation therapy and gross total resection of the brain lesion at West China Second Hospital, and achieved complete remission. In conclusion, the accurate and prompt diagnosis of choriocarcinoma is crucial for a good outcome. Furthermore, in young female patients exhibiting symptoms such as pulmonary bleeding or neurological disturbances following a hydatidiform mole or a normal pregnancy, even in the absence of abnormal uterine bleeding, serum β-HCG levels must be analyzed and a diagnosis of choriocarcinoma must be considered.

Introduction

Gestational trophoblastic disease (GTD) describes various neoplastic disorders originating from the trophoblastic epithelium of the placenta, which are characterized by the distinct tumor marker β-human chorionic gonadotropin (HCG). Gestational trophoblastic neoplasia (GTN) is the malignant form of GTD, which includes invasive moles, choriocarcinoma, placental site trophoblastic tumors (PSTTs) and epithelioid trophoblastic tumors (1). Choriocarcinoma is a highly malignant tumor that may occur during or following any type of pregnancy, including a hydatidiform mole, normal or ectopic pregnancy and abortion (2,3). An accurate and prompt diagnosis of gestational choriocarcinoma is crucial as it is a highly chemosensitive tumor type and thus, the disease exhibits a good prognosis, even in advanced stages (4,5). However, a number of choriocarcinoma cases are often misdiagnosed due to the atypical symptoms of the disease and a lack of clear radiographical evidence. Metastasis to the brain is considered a poor prognostic indicator of choriocarcinoma (6). The aim of the current study was to present the case of a 29-year-old female with International Federation of Gynecology and Obstetrics (FIGO) (7) stage IV gestational choriocarcinoma that was initially misdiagnosed as pulmonary tuberculosis, and to discuss the management of gestational choriocarcinoma with pulmonary and cerebral metastasis.

Case report

On August 15, 2013, a 29-year-old female presented to the local hospital with right-sided chest congestion and pain, which had lasted for 4 months, accompanied by a mild fever, coughing, heavy breathing and palpitations. X-ray examination of the chest revealed an increased number of lung markings, multiple bilateral pulmonary nodules and massive right pleural effusion, and cytopathology revealed hemorrhagic pleural fluid. At the respiratory clinic of the local hospital, pulmonary tuberculosis was diagnosed based on the patient's respiratory symptoms and radiological findings. Subsequently, an anti-tuberculosis regimen of isoniazid (300 mg, daily), rifampicin (450 mg, daily) and ethambutol (750 mg, daily) was administered for 3 months. However, the anti-tuberculosis treatment failed to alleviate the patient's symptoms and 4 months later, the patient experienced neurological disturbances, including severe headaches, dizziness and uncontrolled vomiting.

On December 24, 2013, the patient was transferred to West China Second Hospital (Chengdu, China). Upon obtaining a complete clinical history, the patient reported that the date of her last pregnancy, which was terminated by artificial abortion, was 3 years ago, with two previous full-term vaginal deliveries. The patient's menstrual cycle was regular (28-30 days; 4-6 days duration) with no cessation of menstruation or irregular
uterine bleeding reported. A routine laboratory examination was performed. Chest radiography showed increased lung markings, diffuse infiltrates in each lung and a massive right pleural effusion (Fig. 1). Computed tomography (CT) scans of the lungs and brain revealed irregular multiple bilateral pulmonary nodules with a maximum diameter of 29 mm, right pleural effusion and a cystic mass, 43x35x27 mm in size, in the parietal lobe of the right cerebrum (Fig. 2). The serum $\beta$-HCG level was 655,011.2 mIU/ml (normal level, <2.0 mIU/ml), while other tumor markers, including $\alpha$-fetoprotein, carcinoembryonic antigen, carbohydrate antigen 19-9 and cancer antigen 125, were all within the normal ranges. Transvaginal sonogram and sonohysterography examination were also performed, however the results were unremarkable. Following a consultation, gestational choriocarcinoma with pulmonary and cerebral metastasis [FIGO stage IV; World Health Organization score, 15 (8)] was diagnosed, which had been misdiagnosed as pulmonary tuberculosis previously at the local hospital. After written informed consent was obtained, systemic multi-agent chemotherapy was administered (Table I). Additionally, the patient underwent whole-brain irradiation and neurological surgery. The patient's recovery was monitored by a series of blood or cerebrospinal fluid (CSF) $\beta$-HCG measurements (Table I), chest X-ray examination, CT and magnetic resonance imaging scans. After 11 cycles of chemotherapy, the $\beta$-HCG level was within the normal range. The post-chemotherapy period was excellent, without any major complications. The patient achieved complete remission with a good outcome and follow-up is ongoing.

**Discussion**

Choriocarcinoma is a rare, highly malignant neoplasm of the gestational trophoblast of the placenta, which usually presents as abnormal uterine bleeding. This tumor often demonstrates rapid hematogenous spread to multiple organs, and is associated with high $\beta$-HCG levels and a good response to chemotherapy (4,5,9). Approximately 30% of choriocarcinoma patients exhibit metastasis at the time of diagnosis, which may

<table>
<thead>
<tr>
<th>Course</th>
<th>Chemotherapy regimen</th>
<th>Blood $\beta$-HCG level, mIU/ml</th>
<th>CSF $\beta$-HCG level, mIU/ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>5-FU&lt;sup&gt;a&lt;/sup&gt;</td>
<td>65011.2</td>
<td>1753.7</td>
</tr>
<tr>
<td>2</td>
<td>5-FU&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1420.0</td>
<td>14.6</td>
</tr>
<tr>
<td>3</td>
<td>5-FU&lt;sup&gt;a&lt;/sup&gt;</td>
<td>63.7</td>
<td>7.2</td>
</tr>
<tr>
<td>4</td>
<td>5-FU&lt;sup&gt;a&lt;/sup&gt;</td>
<td>15.7</td>
<td>4.7</td>
</tr>
<tr>
<td>5</td>
<td>5-FU&lt;sup&gt;a&lt;/sup&gt;</td>
<td>9.3</td>
<td>4.7</td>
</tr>
<tr>
<td>6</td>
<td>5-FU&lt;sup&gt;a&lt;/sup&gt;</td>
<td>3.7</td>
<td>4.7</td>
</tr>
<tr>
<td>7</td>
<td>5-FU&lt;sup&gt;a&lt;/sup&gt;</td>
<td>2.9</td>
<td>4.7</td>
</tr>
<tr>
<td>8</td>
<td>EMA/CO&lt;sup&gt;d,e&lt;/sup&gt;</td>
<td>7.7</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>EMA/CO&lt;sup&gt;d&lt;/sup&gt;</td>
<td>&lt;2.0</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>EMA/CO&lt;sup&gt;d&lt;/sup&gt;</td>
<td>&lt;2.0</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>EMA/CO&lt;sup&gt;d&lt;/sup&gt;</td>
<td>&lt;2.0</td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup>24 mg/kg intravenously, days 1-8; <sup>b</sup>5 µg/kg intravenously, days 1-8; <sup>c</sup>15 mg intrathecally, days 2/4/7; <sup>d</sup>100 mg/m² etoposide intravenously on days 1/2, 100 mg/m² + 200 mg/m² MTX intravenously on day 1, 500 µg Act-D intravenously on days 1/2, 600 mg/m² cyclophosphamide intravenously on day 8 and 1 mg/m² vincristine intravenously on day 8. *Due to the increased blood $\beta$-HCG level, the regimen was changed to EMA/CO to prevent the development of chemoresistance. CSF, cerebrospinal fluid; $\beta$-HCG, $\beta$-human chorionic gonadotropin; 5-FU, 5-fluorouracil; Act D, actinomycin D; MTX, methotrexate; EMA/CO, etoposide, MTX, Act D, vincristin and cyclophosphamide.
be attributable to the high affinity exhibited by trophoblastic cells for blood vessels (10,11). The most common metastatic sites of choriocarcinoma are the lungs (80%), vagina (30%), pelvis (20%) and liver (10%). Cerebral metastases occur in ~10% of cases. Despite the aggressive nature of the disease, a cure remains possible if it is treated at an early stage, in accordance with well-established guidelines (12). Notably, following treatment with multi-agent chemotherapy regimens, ~75% of choriocarcinoma patients (FIGO stage IV) are expected to achieve complete or prolonged remission (5,7). Consequently, an accurate and prompt diagnosis is crucial. In addition, the early diagnosis of GTN and the timely administration of chemotherapy may decrease the number of chemotherapy courses required for treatment.

In the present study, the patient presented with right-sided chest congestion and pain that had lasted for 4 months, and was accompanied with a mild fever, coughing, heavy breathing and palpitations. Notably, the patient's menstrual cycle was regular without cessation of menstruation or irregular vaginal bleeding. The patient exhibited no typical symptoms of choriocarcinoma, and the respiratory symptoms and radiological findings were similar to that of pulmonary tuberculosis, resulting in a misdiagnosis and subsequent delay to treatment. The major failure in the diagnosis of this case was that the patient's serum β-HCG levels were initially ignored. Therefore, in young females with symptoms such as pulmonary bleeding or neurological disturbances following a hydatidiform mole or a normal pregnancy, even in the absence of abnormal uterine bleeding, serum β-HCG levels must analyzed and a diagnosis of choriocarcinoma must be considered.

Multi-agent chemotherapy is the standard treatment for high-risk choriocarcinoma. At present, the most commonly used multi-agent treatment regimens are the 5-fluorouracil (5-FU) plus actinomycin D (Act D) (FA regimen) and the etoposide, methotrexate, Act D, vincristin and cyclophosphamide (EMA/CO) regimen. The FA regimen is effective in low- and high-risk GTN patients, but not in PSTT patients. Additionally, it may be administered as a primary chemotherapy regimen for the treatment of high-risk GTN patients (13,14). It is reported that the EMA/CO regimen is considered to be highly effective for the treatment of high-risk GTN, as it exhibits good efficacy and is well-tolerated by patients. In a previous study by Bolis et al (15), the survival rate of high-risk patients treated with the EMA/CO regimen was 88%, and 76% of these patients were alive with no evidence of disease after 5.5 months. Patient survival and complete response to the EMA/CO regimen are affected by a number of factors, such as liver metastasis, antecedent pregnancy and the histopathological diagnosis of choriocarcinoma. The most severe reported toxicity associated with EMA/CO treatment was grade 3-4 leukopenia and febrile neutropenia (16). Brain metastases with or without oncocytic aneurysms may be rapidly controlled by the administration of immediate whole-brain irradiation and intrathecal chemotherapy. Furthermore, surgical intervention may be required in cases of life threatening hemorrhage. The levels of HCG in the serum and CSF are good markers for determining the effect of therapy. However, HCG levels in the CSF may decrease slowly without affecting prognosis (17-19).

In the present study, the patient achieved complete remission following combined treatment with systematic multi-agent chemotherapy, whole-brain radiation therapy and gross total resection of the brain lesion. This case demonstrates the importance of rapidly initiating chemotherapeutic and radiotherapy for FIGO stage IV gestational choriocarcinoma following diagnosis.

References